Drug intelligence / Profile preview

VB24

Development stage: Preclinical
Lead developer: 深圳扬厉医药
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics

Overview

VB24 is a small interfering RNA (siRNA) therapeutic candidate being developed by Zhejiang Yangli Pharmaceutical Technology (VyBio) for the treatment of cardiovascular and renal diseases, including hypertension, chronic kidney disease (CKD), and heart failure. As part of VyBio's CVRM (Cardiovascular, Renal, and Metabolic) pipeline, VB24 utilizes siRNA technology to silence specific, currently undisclosed gene targets involved in the pathogenesis of cardiorenal conditions. The drug is currently in the discovery stage of development.

Beyond the preview

Go deeper on VB24.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VB24.

Explore the full profile